evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,288 questions · 3,354 findings · 516 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 720 · 21.5%GRADE not reported 164 · 4.9%Very low 950 · 28.3%Low 932 · 27.8%Moderate 434 · 12.9%High 154 · 4.6%

POLYPEPTIDE ‐ CERULETIDE vs placebo

Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Levetiracetam vs placebo

Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether ANTIEPILEPTIC ‐ LEVETIRACETAM changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

Vitamin E vs placebo

Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia

VITAMIN E showed no clear difference in tardive dyskinesia: 1. Not improved to a clinically important extent compared with PLACEBO (low certainty).

1 finding from 1 review

Vitamin E vs placebo

Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia

VITAMIN E may leads to lower tardive dyskinesia: 3. Deterioration of symptoms compared with PLACEBO (low certainty).

1 finding from 1 review

Vitamin E vs placebo

Adverse effect: any · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether VITAMIN E changes adverse effect: any compared with PLACEBO (very low certainty).

1 finding from 1 review

Vitamin E vs placebo

Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether VITAMIN E changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

Reduced dose of antipsychotics vs antipsychotic maintenance

Tardive dyskinesia: No clinically important improvement · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia

It is very uncertain whether reduced dose of antipsychotics changes tardive dyskinesia: no clinically important improvement compared with antipsychotic maintenance (very low certainty).

1 finding from 1 review

Switch to another antipsychotic vs antipsychotic cessation

Adverse effects: use of antiparkinsonism drugs · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether switch to another antipsychotic changes adverse effects: use of antiparkinsonism drugs compared with antipsychotic cessation (very low certainty).

1 finding from 1 review

Switch to another antipsychotic vs antipsychotic cessation

Leaving the study early · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether switch to another antipsychotic changes acceptability of the treatment: leaving the study early compared with antipsychotic cessation (very low certainty).

1 finding from 1 review